Cytosorbents (CTSO) Net Income towards Common Stockholders Growth (1y) (2011 - 2026)
Powered by 
Analysis
Cytosorbents (CTSO) Net Income towards Common Stockholders Growth (1y) (2011 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.04 Bn | 177.44 Bn | 7.27 Bn | -47.84% |
| 2 | Intuitive Surgical | 125.02 Bn | 119.81 Bn | 1.96 Bn | 23.94% |
| 3 | Medtronic | 117.84 Bn | 109.02 Bn | 6.34 Bn | 41.36% |
| 4 | Stryker | 105.50 Bn | 102.02 Bn | 4.50 Bn | 44.34% |
| 5 | Boston Scientific | 66.27 Bn | 65.73 Bn | 3.85 Bn | 13.80% |
| 6 | Edwards Lifesciences | 49.60 Bn | 45.35 Bn | 1.35 Bn | -27.18% |
| 7 | Alcon | 33.70 Bn | 32.24 Bn | 1.68 Bn | - |
| 8 | Dexcom | 32.06 Bn | 30.11 Bn | 830.00 Mn | 38.54% |
| 9 | Steris | 21.02 Bn | 20.54 Bn | 684.20 Mn | 12.92% |
| 10 | Cytosorbents | 20.00 Mn | 15.59 Mn | 7.05 Mn | -326.86% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -326.86% |
| Mar 31, 2026 | -246.79% |
| Dec 31, 2025 | 27.36% |
| Sep 30, 2025 | -14.52% |
| Jun 30, 2025 | 145.34% |
| Mar 31, 2025 | 76.74% |
| Dec 31, 2024 | -29.69% |
| Sep 30, 2024 | 69.89% |
| Jun 30, 2024 | 30.21% |
| Mar 31, 2024 | 13.21% |
| Dec 31, 2023 | -661.61% |
| Sep 30, 2023 | 24.65% |
| Jun 30, 2023 | 43.44% |
| Mar 31, 2023 | 18.30% |
| Dec 31, 2022 | 91.77% |
| Sep 30, 2022 | -90.45% |
| Jun 30, 2022 | -132.58% |
| Mar 31, 2022 | -115.13% |
| Dec 31, 2021 | -1,273.27% |
| Sep 30, 2021 | -662.90% |